Company intelligence / Profile preview
Shanghai Aibo Pharmaceutical Technology Co Ltd
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple drug candidates in clinical trials, including ABP2111 for obesity and type 2 diabetes (Phase 2) and ABP1019A for advanced malignant solid neoplasm (Phase 2). A Phase 1b clinical trial for ABP2111Na tablets in patients with type 2 diabetes began recruiting in March 2025, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics.
- Therapeutic areas
- EndocrinologyOncology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Ab Pharma Ltd.
Beyond the preview
Go deeper on Shanghai Aibo Pharmaceutical Technology Co Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Aibo Pharmaceutical Technology Co Ltd.